Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Start CPAP-terapi hos pasienter med obstruktiv søvnapné etter ablasjon ved atrieflimmer (STOP-AFib)

30. september 2026 oppdatert av: Beijing Anzhen Hospital

Start CPAP-terapi hos pasienter med obstruktiv søvnapné etter kateterablasjon for atrieflimmer: En multikenter, åpen, randomisert klinisk studie

Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.

This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.

Participants will:

  • Be randomly assigned to either the CPAP group or the usual care group.
  • If in the CPAP group, use a CPAP device for 12 months.
  • Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization.
  • Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.

Studieoversikt

Detaljert beskrivelse

Atrial fibrillation (AF) is a common sustained cardiac arrhythmia, with recurrence rates of 20-45% after catheter ablation. Obstructive sleep apnea (OSA) is a common comorbidity and an important modifiable risk factor for post-ablation AF recurrence. Continuous positive airway pressure (CPAP) is the standard therapy for OSA, but its effect on reducing AF recurrence after ablation remains uncertain.This study aims to evaluate whether, in patients with OSA and AF who undergo catheter ablation, the postoperative CPAP treatment can increase the rate of no recurrence of atrial arrhythmia within one year compared to usual treatment. This prospective, multicenter, open-label, parallel-group randomized controlled trial will be conducted at approximately 20 centers in mainland China. Approximately 658 adults aged 18-75 years with persistent AF and diagnosed OSA who have successfully undergone first-time catheter ablation will be enrolled.

After confirmation of eligibility and informed consent, participants will be randomized in a 1:1 ratio to receive either CPAP therapy plus usual care or usual care alone. CPAP therapy will be provided for 12 months, with treatment parameters determined by pressure titration, and adherence monitored using device-recorded data. Participants in the usual care group will receive standard AF management and standardized education regarding OSA; additional OSA treatments outside the study protocol will be permitted and documented.All participants will receive guideline-directed medical therapy for AF.

Follow-up will last at least 12 months, with assessments at approximately 1, 3, 6, and 12 months after randomization. Atrial arrhythmia monitoring will be performed primarily using ambulatory ECG recorders.

The primary outcome is freedom from atrial arrhythmia recurrence within 12 months after randomization. Secondary outcomes include atrial arrhythmia recurrence patterns, arrhythmia-related interventions, atrial fibrillation burden, and changes in quality-of-life and psychological assessment scores.

Studietype

Intervensjonell

Registrering (Antatt)

658

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Tianjin, Kina
        • Har ikke rekruttert ennå
        • Tianjin Medical University Second Hospital
        • Hovedetterforsker:
          • Xiaoyun Zhao, Professor
        • Ta kontakt med:
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100029
        • Rekruttering
        • Beijing Anzhen Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jiang Xie, Professor
        • Hovedetterforsker:
          • Shaoping Nie, Professor
        • Hovedetterforsker:
          • Deyong Long, Professor
      • Beijing, Beijing Municipality, Kina, 100730
        • Har ikke rekruttert ennå
        • Beijing Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wei Gong, Professor
      • Beijing, Beijing Municipality, Kina, 102206
        • Har ikke rekruttert ennå
        • Peking University International Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yanwen Jiang, Professor
      • Beijing, Beijing Municipality, Kina, 100020
        • Har ikke rekruttert ennå
        • Beijing Chaoyang Hospital, Capital Medical University
        • Ta kontakt med:
          • Zhiling Zhao, Professor
          • Telefonnummer: +86-10-85231000
          • E-post: cysleep@163.com
        • Hovedetterforsker:
          • Zhiling Zhao, Professor
      • Beijing, Beijing Municipality, Kina, 100035
        • Har ikke rekruttert ennå
        • Beijing Jishuitan Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yang Cheng, Professor
    • Fujian
      • Fuzhou, Fujian, Kina, 350001
        • Har ikke rekruttert ennå
        • Fujian Medical University Union Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiangqi Chen, Professor
      • Fuzhou, Fujian, Kina, 350004
        • Har ikke rekruttert ennå
        • First Affiliated Hospital of Fujian Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ningfang Lian, Professor
      • Zhangzhou, Fujian, Kina, 363000
        • Har ikke rekruttert ennå
        • Zhangzhou Hospital of Fujian Province
        • Ta kontakt med:
        • Hovedetterforsker:
          • Li Lin, Professor
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Har ikke rekruttert ennå
        • People's Hospital of Guangxi Zhuang Autonomous Region
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mingming Zhao, Professor
    • Hebei
      • Langfang, Hebei, Kina, 065000
        • Har ikke rekruttert ennå
        • Langfang People's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zengming Xue, Professor
      • Shijiazhuang, Hebei, Kina, 050000
        • Rekruttering
        • Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine
        • Ta kontakt med:
          • Linyi Huang, Professor
          • Telefonnummer: +86-0311-85837801
          • E-post: 496777551@qq.com
        • Hovedetterforsker:
          • Linyi Huang, Professor
      • Xingtai, Hebei, Kina, 055250
        • Rekruttering
        • The Ninth Hospital of Xingtai
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zhanwei Liu, Professor
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150086
        • Har ikke rekruttert ennå
        • Second Affiliated Hospital of Harbin Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wei Meng, Professor
    • Henan
      • Shangqiu, Henan, Kina
        • Har ikke rekruttert ennå
        • Shangqiu First People's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Renshan Niu, Professor
      • Zhengzhou, Henan, Kina, 450052
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Zhengzhou University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gangqiong Liu, Professor
    • Hubei
      • Wuhan, Hubei, Kina, 430014
        • Har ikke rekruttert ennå
        • Wuhan No. 1 Hospital
        • Ta kontakt med:
          • Zhihua Yu, Professor
          • Telefonnummer: +86 02785332144
          • E-post: whyu027@163.com
        • Hovedetterforsker:
          • Zhihua Yu, Professor
      • Wuhan, Hubei, Kina, 430056
        • Har ikke rekruttert ennå
        • Wuhan Asia General Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ning Man, Professor
    • Hunan
      • Changsha, Hunan, Kina, 410011
        • Har ikke rekruttert ennå
        • The Second Xiangya Hospital of Central South University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ruoyun Ouyang, Professor
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Nanjing Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ning Ding, Professor
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Har ikke rekruttert ennå
        • The First Hospital of Jilin University
        • Ta kontakt med:
          • Haibo Yuan, Professor
          • Telefonnummer: +86-431-88782222
          • E-post: hyuan@jlu.edu.cn
        • Hovedetterforsker:
          • Haibo Yuan, Professor
    • Liaoning
      • Dalian, Liaoning, Kina, 116011
        • Har ikke rekruttert ennå
        • First Affiliated Hospital of Dalian Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Haiying Tang, Professor
      • Shenyang, Liaoning, Kina, 110004
        • Har ikke rekruttert ennå
        • Shengjing Hospital of China Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Li Xiao, Professor
      • Shenyang, Liaoning, Kina, 110001
        • Har ikke rekruttert ennå
        • First Affiliated Hospital of China Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wenyang Li, Professor
    • Shandong
      • Dongying, Shandong, Kina, 257034
        • Har ikke rekruttert ennå
        • Shengli Oilfield Central Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiangfei Liu, Professor
      • Linyi, Shandong, Kina, 276003
        • Har ikke rekruttert ennå
        • Linyi People's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Li Wei, Professor
    • Shanxi
      • Taiyuan, Shanxi, Kina, 030001
        • Har ikke rekruttert ennå
        • Second Hospital of Shanxi Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiaoling Gao, Professor
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300222
        • Har ikke rekruttert ennå
        • Tianjin Chest Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Fang Zhao, Professor
    • Yunnan
      • Kunming, Yunnan, Kina
        • Har ikke rekruttert ennå
        • Yan'an Hospital of Kunming City
        • Ta kontakt med:
          • Xia Jiang, Professor
          • Telefonnummer: +86-0871-63211073
          • E-post: 378972370@qq.com
        • Hovedetterforsker:
          • Xia Jiang, Professor
    • Zhejiang
      • Ningbo, Zhejiang, Kina, 315010
        • Har ikke rekruttert ennå
        • First Affiliated Hospital of Ningbo University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maoqing Tong, Professor

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Patients must meet all of the following conditions to be eligible for the study:

  • Age 18-75 years.
  • Patients with persistent AF who received catheter ablation for the first time.
  • Diagnosed with OSA.
  • Able to tolerate CPAP therapy.
  • Capable of understanding and complying with the study protocol.
  • Willing to sign the informed consent form.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from the study:

  • Secondary AF.
  • Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).
  • Left ventricular ejection fraction < 30%.
  • Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).
  • Pregnant or breastfeeding women.
  • History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.
  • History of stroke or transient ischemic attack within 6 months prior to screening.
  • Perioperative complications related to the ablation procedure occurring prior to randomization.
  • Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.
  • Life expectancy < 1 year.
  • Central sleep apnea.
  • Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with > 1 episode of respiratory failure or hypercapnia.
  • Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.
  • Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.
  • Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.
  • Current participation in other drug or device trials.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CPAP Group

Usual care combined with CPAP therapy.

Participants receive CPAP therapy provided by the research team. Treatment parameters are determined following auto-titrating or manual pressure titration. Prior to treatment initiation, participants receive training on device usage, mask fitting and adjustment, equipment cleaning and maintenance, and data transmission methods. Study physicians and technicians provide support to address any CPAP-related discomfort. 'Good adherence' is defined as device usage of ≥ 4 hours per night on ≥ 70% of days.

Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives.

Aktiv komparator: Usual Care Group

Standard of care for atrial fibrillation and usual care for OSA (health education). Researchers advise participants to visit sleep centers or pulmonology departments for further assessment/treatment at their own discretion, but do not intervene in their choice of OSA therapy or provide the study CPAP device.

Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of freedom from atrial arrhythmia recurrence.
Tidsramme: Within 12 months

Recurrence is defined as a composite of:

  1. Any documented atrial arrhythmia (AF / Atrial Tachycardia [AT] / Atrial Flutter [AFL]) lasting 30 seconds after a 3-month blanking period;
  2. Use of Class I or III AADs after the 3-month blanking period;
  3. Cardioversion performed after the 3-month blanking period;
  4. Repeat catheter ablation performed at any time.
Within 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Forekomst av dokumentert atrieflimmer (AF/AFL/AT) som varer ≥30 sekunder.
Tidsramme: Innen 12 måneder (etter en 3-måneders blankingperiode).
Innen 12 måneder (etter en 3-måneders blankingperiode).
Forekomst av dokumentert AF som varer ≥30 sekunder.
Tidsramme: Innen 12 måneder (etter en 3-måneders blankingsperiode).
Innen 12 måneder (etter en 3-måneders blankingsperiode).
Forekomst av dokumentert AT som varer ≥30 sekunder.
Tidsramme: Innen 12 måneder (etter en 3-måneders blankingsperiode).
Innen 12 måneder (etter en 3-måneders blankingsperiode).
Forekomst av dokumentert AFL som varer ≥30 sekunder.
Tidsramme: Innen 12 måneder (etter en 3-måneders blankingperiode).
Innen 12 måneder (etter en 3-måneders blankingperiode).
Andel pasienter som bruker antiarytmika i klasse I eller III.
Tidsramme: Innen 12 måneder (etter en 3-måneders blankingsperiode).
Innen 12 måneder (etter en 3-måneders blankingsperiode).
Andel pasienter som gjennomgår kardioversjon.
Tidsramme: Innen 12 måneder (etter en 3-måneders blankingsperiode).
Innen 12 måneder (etter en 3-måneders blankingsperiode).
Andel pasienter som gjennomgår repetert kateterablasjon.
Tidsramme: Innen 12 måneder.
Innen 12 måneder.
AF-byrde
Tidsramme: Innen 12 måneder.
Innen 12 måneder.
Change in quality of life assessed by the Atrial Fibrillation Effect on Quality-of-Life questionnaire.
Tidsramme: Baseline, Month 12.

Scores range from 0 to 100, where higher scores indicate a better quality of life.

Baseline, Month 12.
Change in anxiety and depression assessed by the Hospital Anxiety and Depression Scale.
Tidsramme: Baseline, Month 12.

Scores for both the anxiety and depression subscales range from 0 to 21, where higher scores indicate worse anxiety and depression.

Baseline, Month 12.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. mai 2026

Primær fullføring (Antatt)

31. januar 2029

Studiet fullført (Antatt)

31. januar 2029

Datoer for studieregistrering

Først innsendt

25. februar 2026

Først innsendt som oppfylte QC-kriteriene

25. februar 2026

Først lagt ut (Faktiske)

2. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere